Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Obesity01:24

Obesity

1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

268
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
268
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

286
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
286
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

191
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
191
Nursing Clinical Information System01:27

Nursing Clinical Information System

1.3K
Nursing Clinical Information System (NCIS)
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include:
1.3K
Clinical Trials01:16

Clinical Trials

10.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: PAK4 phosphorylates and inhibits AMPKα to control glucose uptake.

Nature communications·2025
Same author

Telomere stabilization by metformin mitigates the progression of atherosclerosis via the AMPK-dependent p-PGC-1α pathway.

Experimental & molecular medicine·2024
Same author

PAK4 phosphorylates and inhibits AMPKα to control glucose uptake.

Nature communications·2024
Same author

Inhibitory Regulation of FOXO1 in PPARδ Expression Drives Mitochondrial Dysfunction and Insulin Resistance.

Diabetes·2024
Same author

Author Correction: Multiparity increases the risk of diabetes by impairing the proliferative capacity of pancreatic β cells.

Experimental & molecular medicine·2023
Same author

Multiparity increases the risk of diabetes by impairing the proliferative capacity of pancreatic β cells.

Experimental & molecular medicine·2023

Related Experiment Video

Updated: Feb 7, 2026

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.9K

Obesity and Erectile Dysfunction: From Bench to Clinical Implication.

Ki Hak Moon1, So Young Park2, Yong Woon Kim3

  • 1Department of Urology, Yeungnam University College of Medicine, Daegu, Korea.

The World Journal of Men'S Health
|August 7, 2018
PubMed
Summary

Obesity and erectile dysfunction (ED) share common causes like inflammation and insulin resistance. Metformin may improve ED treatment by addressing these metabolic issues, especially when combined with ED medications.

Keywords:
Erectile dysfunctionMetforminObesityPhosphodiesterase 5 inhibitors

More Related Videos

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.0K
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
08:03

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

15.1K

Related Experiment Videos

Last Updated: Feb 7, 2026

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.9K
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

1.0K
Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents
08:03

Intracavernosal Pressure Recording to Evaluate Erectile Function in Rodents

Published on: June 6, 2018

15.1K

Area of Science:

  • Endocrinology
  • Urology
  • Public Health

Background:

  • Obesity is a global health concern linked to erectile dysfunction (ED).
  • Shared pathophysiologic processes include oxidative stress, inflammation, and insulin/leptin resistance.
  • ED severity correlates with obesity and other comorbidities.

Purpose of the Study:

  • To explore the links between obesity and ED.
  • To discuss combined treatment strategies for obese patients with ED.
  • To evaluate metformin's potential role in improving ED treatment efficacy.

Main Methods:

  • Review of existing literature on obesity, ED, and metabolic derangements.
  • Analysis of pathophysiologic connections between obesity and ED.
  • Examination of metformin's effects on oxidative stress, inflammation, and insulin/leptin resistance.

Main Results:

  • Metformin demonstrates potential in reducing oxidative stress, inflammation, and body weight.
  • Combination therapy with metformin and phosphodiesterase 5 inhibitors shows improved erectile function in specific patient groups.
  • Addressing metabolic issues may enhance the effectiveness of ED treatments.

Conclusions:

  • Treating metabolic derangements in obese patients with ED can improve treatment outcomes.
  • Metformin offers a promising therapeutic option for managing obesity-related ED.
  • Combined treatment modalities hold potential for refractory ED cases.